AUTHORS
Nathan Martin, PhD, Irene Manrique2, Nicholas Stong, PhD3, Saleh Tamim4, Shari Kaiser, PhD5, Noffar Bar, MD6, Thomas Martin, MD7, Craig Hofmeister, MD, MPH8, Maria-Victoria Mateos Jr, MD, PhD9, Jesus San-Miguel Sr, Md, PhD10, Luciano J. Costa, MD, PhD11, Colin Godwin, MD12, Bruno Paiva, PhD13
AFFILIATIONS
1 Bristol Meyers Squibb, Seatle, United States
2 Cancer Center Clinica Universidad de Navarra, CIMA Universidad de Navarra, IDISNA, CIBERONC, Pamplona, Spain
3 Bristol Meyers Squibb, Seatle, United States
4 Bristol Meyers Squibb, Seatle, United States
5 Bristol Meyers Squibb, Seatle, United States
6 Yale School of Medicine, New Haven, United States
7 University of California at San Francisco, San Francisco, United States
8 Winship Cancer Institute of Emory University, Atlanta, United States
9 Hospital Universitario de Salamanca, Salamanca, Spain
10 Cancer Center Clinica Universidad de Navarra, CIMA Universidad de Navarra, IDISNA, CIBERONC, Pamplona, Spain
11 University of Alabama at Birmingham (UAB) O'Neal Comprehensive Cancer Center, Birmingham, United States
12 Bristol Meyers Squibb, Seatle, United States
13 Cancer Center Clinica Universidad de Navarra, CIMA Universidad de Navarra, IDISNA, CIBERONC, Pamplona, Spain
ABSTRACT
Background: TCE are redefining the treatment of MM. The growing number of options urges optimal patient-drug selection to maximize efficacy and reduce toxicity. Owing to TCE mode of action, immune monitoring is expected to contribute to treatment individualization. However, there is limited understanding of how T-cell fitness associates with PFS, the effect that TCE have on T-cell phenotypes, and if there are T-cell signatures linked to the duration of response. Another unanswered question is the role of MRD after TCE. Furthermore, isolating the TCE-monotherapy components to these questions is increasingly challenging since TCE are more frequently being combined and sequenced with other drugs. Thus, we aimed to define the clinical significance of immune and MRD monitoring in RRMM pts treated with single-agent alnuctamab, a 2+1 IgG1 TCE that binds BCMA and CD3ε receptors on tumor and T cells, respectively.
Methods: This study included 106 RRMM pts with translational analysis carried within the CC-93269-MM-001 phase 1 trial. Immune profiling was performed in bone marrow (BM) at baseline (n=77) and at C2D1 (n=41) using multidimensional and computation flow cytometry for automated T-cell characterization (162 clusters). Baseline BM samples from 27 pts underwent scRNA/TCR-seq. WGS of CD138+ tumor cells and matched germline DNA was performed at baseline (n=60) and post-treatment (n=12). MRD was assessed at C2D1 (n=106) using EuroFlow NGF with 2x10-6 limit of detection.
Results: We first investigated if T-cell phenotypes prior to treatment correlated with demographics and clinical characteristics. After Bonferroni correction, there were no significant associations between T-cell clusters and sex, age, ISS, cytogenetic risk or soluble BCMA. The finding that the individual effect of host and tumor in pts' immune status cannot be fully dissected, suggests that immune profiling could act as a surrogate of their cumulative effect in T‐cell fitness.
We next investigated if baseline T-cell phenotypes were associated with PFS. In a multivariate analysis adjusted for ISS, involved FLC levels and number of prior lines of therapy, effector memory CD8+ T cells were independently associated with PFS (HR 0.7, 95% CI 0.6–0.9; p=0.015). Pts with high vs low frequencies had median PFS of 37 vs 3 months, respectively. scRNA/TCR-seq unveiled trends between MRD status and the percentages of naïve B cells and CD16+ non-classical monocytes. Only two pts had BCMA monoallelic loss at baseline and both achieved MRD negativity. These results highlight how immune monitoring could be complementary to other risk-factors.
We next investigated the effect of TCE on T-cell phenotypes from baseline to C2D1. There were 8 clusters contracting, namely Tregs and other CD4 subsets without expression of immune checkpoints. There were 8 clusters expanding, which often expressed CD28 and ≥1 immune checkpoint; by contrast, CD25, CD57 and CD127 were negative. These results suggest ongoing differentiation after initial activation of T-cell responses.
The clinical significance of MRD was investigated at C2D1. MRD positive pts had 11-fold increased hazard of progression or death compared to those with undetectable MRD (HR 10.8, 95% CI 4.2–27.7, p<0.001). The 3-year PFS rates of MRD positive vs negative pts were 0% and 65%, respectively. These results demonstrate that, similarly to other agents, MRD after single-agent TCE is strongly associated with pts’ survival and that persistent MRD inevitably results in progressive disease.
BCMA biallelic loss was found in only one pt who relapsed after MRD negativity. Thus, we investigated if T-cell signatures after treatment with TCE could improve outcome prediction beyond tumor genomics and MRD response. After adjusting for MRD status, there were 4 T-cell clusters that independently predicted different PFS, namely among MRD negative patients. Interestingly, these were CD4- and CD8-, suggesting that the balance between T-cell thymic replenishment and death after TCE-mediated cytotoxicity may impact duration of response in MRD negative pts.
Conclusions: This is one of the largest multiomics studies in RRMM pts treated with single-agent TCE. Our results showcase how immune monitoring may help in predicting outcomes beyond tumor burden and genomics. We confirmed that persistent MRD was associated with inevitable risk of relapse, and unveiled that immune monitoring may help in predicting the duration of response in MRD negative pts.
DISCLOSURES
Bruno Paiva, PhD: Roche - Honoraria; GSK - Honoraria; Becton/Dickinson Biosciences - Honoraria; BMS-Celgene - Honoraria; Sanofi - Honoraria; Johnson & Johnson - Honoraria; AstraZeneca - Research Funding; Sanofi - Research Funding; Beigene - Research Funding; Roche - Research Funding; GSK - Research Funding; GSK - Consultancy (Includes expert testimony); Roche - Consultancy (Includes expert testimony); Sanofi - Consultancy (Includes expert testimony); Johnson & Johnson - Consultancy (Includes expert testimony); BMS-Celgene - Consultancy (Includes expert testimony)